{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-000233","form_type":"8-K","ticker":"TERN","cik":"0001831363","company_name":"Terns Pharmaceuticals, Inc.","filed_at":"2023-01-05T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.908254+00:00","generated_at":"2026-06-20T19:48:39.724138+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Terns Pharmaceuticals details 2023 clinical milestones; cash runway to 2026","bullets":["Plan to initiate US Phase 1 trial for TERN-701 (CML) in H2 2023; top-line readouts 2024. Due to IRA, will not seek US approval for Ph+ ALL.","Phase 2a DUET trial of TERN-501 (NASH) expects enrollment completion Q1 2023, top-line data Q3 2023; first combo of THR-β and FXR agonist.","Obesity program TERN-601 (GLP-1 agonist) Phase 1 start H2 2023, top-line data in 2024; preclinical data to be published.","Cash runway extended to 2026: $293M adjusted cash includes $106M net from Dec 2022 equity offering; excludes potential collaborations."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-000233","json":"https://secwatch.observer/filing/0000950170-23-000233.json","markdown":"https://secwatch.observer/filing/0000950170-23-000233.md","text":"https://secwatch.observer/filing/0000950170-23-000233.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/0000950170-23-000233-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1831363/000095017023000233/tern-20230105.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-20T19:48:39.724138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}